In seeking a possible mechanism underlying the effects of CypA on NASH, we found that treatment with the CypA inhibitor directly suppressed hepatic lipid accumulation in the MCD diet group. This evidence concerns the gene PPIA and metabolic dysfunction-associated steatohepatitis.